Why IMU is a multi multi bagger, page-27400

I'm not backing out on anything. You are (very poorly) arguing semantics to completely detract from the fact that IMU changed their trial design around the time a patient died as a direct result of monotherapy treatment with their drug.

You continue to spout of the fact that the B Cell platform is worth hundreds of millions, despite the company rushing patients into combination dosing and then failing to provide any sort of market update on the safety/efficacy of said combination. Now they are terminating the trial at ~30% planned recruitment. This, at a time the IP is all but removed from investor presentations while investors continue to be diluted by management chasing someone else's second grade IP in an effort to keep the gravy train rollin', all while LC takes home a cool ~$2.5m annually.

LC is getting paid ~$10k every day while PH has hedged half his IMU holding with dodgy loans to prop up his other trashed companies. When does it start to click? You were wrong about their B Cell strategy and now I'm telling you why you're wrong about the valuation.

Please stop tagging me here.